CNBC·2026-10-02 23:20· 17 天前AI 评分43

礼来和诺和诺德为何押注胰淀素，推动 GLP-1 后新一波减重药物

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

AI 导读

礼来和诺和诺德正在开发新的胰淀素药物，作为治疗肥胖和糖尿病的另一种生物学手段。

来源：CNBC · cnbc.com